Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tafamidis
Pharma
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Angus Liu
Apr 22, 2024 10:55am
Alnylam's last-minute Amvuttra trial change raises doubts
Feb 15, 2024 11:26am
FDA spurns Alnylam's Onpattro in ATTR-CM despite adcomm backing
Oct 9, 2023 9:54am
Pfizer's tafamidis will hold its own against new meds: analysts
Sep 18, 2023 3:05pm
FDA casts doubt on Alnylam's Onpattro in ATTR-CM
Sep 11, 2023 11:15am